1. Suou T, Tanaka K, Okano J, Shiota G, Horie Y, Horie Y, Kawasaki H. A case with hepatic fibrosis showing ascites and esophageal varices induced by oral UFT(R) administration. Hepatol Res 2002;22:161-165.
2. Palmeri S, Gebbia V, Russo A, Armata MG, Gebbia N, Rausa L. Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer 1990;61:475-478.
3. Kobayashi F, Ikeda T, Sakamoto N, Kurosaki M, Tozuka S, Sakamoto S, Fukuma T, Marumo F, Sato C. Severe chronic active hepatitis induced by UFTR containing tegafur and uracil. Dig Dis Sci 1995;40:2434-2437.
4. Suou T, Maruyama S, Nakamura H, Kishimoto Y, Abe J, Tanida O, Yamada S, Kawasaki H. Increase in serum 7S domain of type IV collagen and N-terminal propeptide of type III procollagen levels with normal serum transaminase levels after long-term oral administration of Tegaful-Uracil. Hepatol Res 2002;24:184.
5. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis